Synapse - Works

Results (4760)

Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study

Meeting Abstract

Reidy, D. L.; Kulke, M. H.; Wolin, E. M.; Singh, S.; Ferone, D.; Mirakhur, B.; Massien, C.; Houchard, A.; Caplin, M. E.; Baudin, E.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM)

Meeting Abstract

Reardon, D. A.; De Groot, J. F.; Colman, H.; Jordan, J. T.; Daras, M.; Clarke, J. L.; Nghiemphu, P. L.; Gaffey, S. C.; Peters, K. B.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM)

Meeting Abstract

Reardon, D. A.; Kaley, T. J.; Dietrich, J.; Lim, M.; Dunn, G. P.; Gan, H. K.; Cloughesy, T. F.; Clarke, J. L.; Park, A. J.; Macri, M. J.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Richter, J. R.; Martin, T. G.; Vij, R.; Cole, C.; Atanackovic, D.; Zonder, J. A.; Kaufman, J. L.; Mikhael, J.; Bensinger, W.; Dimopoulos, M. A.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status

Meeting Abstract

Razavi, P.; Cecchi, F.; Ross, D. S.; Middha, S.; Zehir, A.; Arcila, M. E.; Hembrough, T. A.; Berger, M. F.; Scaltriti, M.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)

Meeting Abstract

Powles, T.; Motzer, R. J.; Escudier, B. J.; Pal, S. K.; Kollmannsberger, C. K.; Pikiel, J.; Gurney, H.; Rha, S. Y.; Park, S. H.; Geertsen, P. F.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa)

Meeting Abstract

Pomerantz, M.; Wang, X. V.; Kantoff, P. W.; Xie, W.; Kohli, M.; Lee, G. S. M.; Wang, E.; Chen, Y. H.; Hahn, N. M.; Jarrard, D. F.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase I/II study of mogamulizumab, an anti-CCR4 antibody targeting regulatory T cells in advanced cancer patients

Meeting Abstract

Plitas, G.; Wu, K.; Carlson, J.; Cimaglia, N.; Morrow, M.; Rudensky, A. Y.; Wolchok, J. D.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone

Meeting Abstract

Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save